Inovio Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
I am Charles Duncan. I am a senior bio technology analyst here and a managing director. This is the part of the program where I carry my lunch around for the rest of the day and happily enjoy it usually for dinner. But that's because I'm usually very engaged in helping companies to help investors understand their growth opportunities. And the next presenting company I think requires a lot of understanding.
And so, we are very excited to cover Inovio Pharmaceuticals for a long time. We currently cover the stock with an overweight rating and a $12 price target. Inovio arguably is moving into a very transformational time in its evolution with a Phase 3 ongoing which could readout in the second half of next year.
So, it is a pleasure to introduce Dr. Joseph Kim who is the Company's President, CEO and one of its founders. So Joseph, why don't you come up and tell the audience a little bit about the future and then I'll ask you some questions?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |